Nautilus Biotechnology (NAUT) Competitors

Tenaya Therapeutics (NASDAQ:TNYA) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.

Which has more risk and volatility, TNYA or NAUT?

Tenaya Therapeutics has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Is TNYA or NAUT more profitable?

Nautilus Biotechnology's return on equity of -28.85% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.97%	-67.83%
Nautilus Biotechnology	N/A	-28.85%	-24.93%

Do insiders and institutionals have more ownership in TNYA or NAUT?

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 32.8% of Tenaya Therapeutics shares are held by company insiders. Comparatively, 40.5% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has better earnings and valuation, TNYA or NAUT?

Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$124.08M	-$1.53	-1.27
Nautilus Biotechnology	N/A	N/A	-$63.67M	-$0.56	-4.66

Does the MarketBeat Community believe in TNYA or NAUT?

Tenaya Therapeutics received 27 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 79.49% of users gave Tenaya Therapeutics an outperform vote while only 20.00% of users gave Nautilus Biotechnology an outperform vote.

Company	Underperform	Outperform
Tenaya Therapeutics	Outperform Votes 31 79.49%	Underperform Votes 8 20.51%
Nautilus Biotechnology	Outperform Votes 4 20.00%	Underperform Votes 16 80.00%

Do analysts rate TNYA or NAUT?

Tenaya Therapeutics currently has a consensus target price of $15.25, suggesting a potential upside of 686.08%. Nautilus Biotechnology has a consensus target price of $4.50, suggesting a potential upside of 72.41%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nautilus Biotechnology	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media favor TNYA or NAUT?

In the previous week, Nautilus Biotechnology had 8 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 11 mentions for Nautilus Biotechnology and 3 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.29 beat Nautilus Biotechnology's score of 0.23 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tenaya Therapeutics beats Nautilus Biotechnology on 9 of the 15 factors compared between the two stocks.